Monoclonal Antibody Infusion Physician Portal

ACMH can administer available monoclonal antibody treatments for COVID-19 positive patients who meet specific criteria and for whom the antibodies may be an effective treatment.

ACMH is pleased to be among the health care organizations in Pennsylvania offering monoclonal antibody treatment, which is authorized by the FDA for emergency use in the treatment of COVID-19.

This one-time infusion may help keep certain individuals with mild to moderate COVID-19 from progressing in their illness to severe disease and may make it less likely that a patient would need to go to the emergency department or need hospitalization.

ACMH is using monoclonal antibody infusion treatment products in the outpatient infusion center located at the Health and Wellness Education Pavilion, 79 Glade Drive, Kittanning, PA.

For Providers: Ordering Monoclonal Antibody Infusion for Patients

If you would like to order the Monoclonal Antibody Infusion for a patient, download this PROVIDER ORDER PACKET

Complete and fax the forms to 724-543-8855.

 

 

Monoclonal Antibody Infusion: Indications for Use

IMPORTANT!

Symptom onset not more than 7 days prior
Patient is currently symptomatic and not hypoxic (does not require supplemental 02 beyond baseline)
Positive Covid-19 test (antigen or PC) by a medical institution (no home test) 

Primary Consideration:
  • Pregnant
  • Current Cancer Treatment
  • Solid Organ Transplant Recipient
  • Hematopoetic Cell Transplant Recipient
  • Severe Primary Immunodeficiency
  • AIDS (CD4<200 or <15%)
  • Age 65 or older with loss of 2 or more ADLs Bathing, Eating, Dressing, Transferring, Toileting, Continence

Secondary Consideration:
  • Age 75 or older and unvaccinated
  • Age 65 or older unvaccinated with evidence of clinical risk factors
  • Age 65 or older unvaccinated
  • Under age 65, unvaccinated with evidence of clinical risk factors
  • Age 75 or older vaccinated
  • Age 65 or older vaccinated with evidence of clinical risk factors
  • Age 65 or older vaccinated
  • Under age 65 vaccinated with evidence of clinical risk factors


Monoclonal Antibody Infusion: Limitations of Use

Not authorized for use in patients:

  • Who are hospitalized due to COVID-19
  • Who require O2 therapy due to COVID-19
  • Who require an increase in baseline O2 flow rate due to COVID-19

Monoclonal antibodies, such as casirivimab and imdevimab, may be associated with worse clinical outcomes when administered to hospitalized patients requiring high flow oxygen or mechanical ventilation with COVID-19.

There is limited experience treating pregnant women or breastfeeding mothers with bamlanivimab/etesevimab. For a mother and unborn baby, the benefit of receiving bamlanivimab/etesevimab may be greater than the risk from the treatment. If your patient is pregnant or breastfeeding, discuss options and specific situation with the patient and health care provider.
 

Monoclonal Antibody Infusion: Infusion Considerations

With many infusions, there is a risk of allergic reaction to the infusion, albeit reactions to these medications requiring discontinuation are very rare. The infusion center has trained staff and appropriate medications to address any reaction, including: fever, chills, nausea, headache, shortness of breath, low blood pressure, wheezing, swelling of lips, face, or throat, rash including hives, itching, muscle aches, and dizziness.
 

COVID-19 Vaccines and Monoclonal Antibody Infusion

Per the CDC, COVID-19 vaccination should be deferred for at least 90 days after receiving monoclonal antibody infusion.

Persons who have received a COVID-19 vaccine may receive monoclonal antibody at any point after vaccination, if the patient is a candidate based on COVID-19 disease.
 

Patient and Caregiver Information

Click HERE to read a Fact Sheet for Patients, Parents and Caregivers on Sotrovimab.